A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
Martina Puglisi, L Rhoda Molife, Maja Ja de Jonge, Khurum H Khan, Leni van Doorn, Martin D Forster, Montserrat Blanco, Martin Gutierrez, Catherine Franklin, Todd Busman, Jianning Yang, Ferry Alm Eskens, Martina Puglisi, L Rhoda Molife, Maja Ja de Jonge, Khurum H Khan, Leni van Doorn, Martin D Forster, Montserrat Blanco, Martin Gutierrez, Catherine Franklin, Todd Busman, Jianning Yang, Ferry Alm Eskens
Abstract
Aim: This Phase I study investigated safety of navitoclax and docetaxel in patients (n = 41) with advanced solid tumors. Patients & methods: Two navitoclax plus docetaxel dosing schedules (21 and 28 days) were evaluated. Maximum tolerated dose, dose-limiting toxicities and preliminary antitumor activity were assessed. Results: Ten (24%) patients experienced dose-limiting toxicities; dose-escalation cohorts: n = 7 (21-day schedule: n = 5; 28-day schedule: n = 2) and 21-day expanded safety cohort: n = 3. Navitoclax 150-mg days 1-5 every 21 days with docetaxel 75 mg/m2 day 1 was the maximum tolerated dose and optimal schedule. Adverse events included thrombocytopenia (63%), fatigue (61%), nausea (59%) and neutropenia (51%). Four confirmed partial responses occurred. Conclusion: Navitoclax 150-mg orally once/day was safely administered with docetaxel. Myelosuppression limited dose escalation; antitumor activity was observed. Clinical trial registration: NCT00888108 (ClinicalTrials.gov).
Keywords: ABT-263; Phase I; apoptosis; docetaxel; navitoclax.
Source: PubMed